Obatoclax was developed as a pan-BH3 mimetic to induce apoptosis of cancer cells by disrupting multiple interactions, including those between anti-apoptotic BCL2 family proteins (BCL2, BCLXL, and MCL1) and BAX and BAK interactions [61]. This evidence concerns the gene BCL2L1 and cancer.